This is particularly important for the development of patient-directed therapies because the aberrant products of Scn1a missense mutations are potentially expressed, thus representing a novel therapeutic target that is absent from haploinsufficient models of DS. This evidence concerns the gene SCN1A and Dravet syndrome.